BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36517209)

  • 1. Exploring the Effect of Halogenation in a Series of Potent and Selective A
    Prieto-Díaz R; González-Gómez M; Fojo-Carballo H; Azuaje J; El Maatougui A; Majellaro M; Loza MI; Brea J; Fernández-Dueñas V; Paleo MR; Díaz-Holguín A; Garcia-Pinel B; Mallo-Abreu A; Estévez JC; Andújar-Arias A; García-Mera X; Gomez-Tourino I; Ciruela F; Salas CO; Gutiérrez-de-Terán H; Sotelo E
    J Med Chem; 2023 Jan; 66(1):890-912. PubMed ID: 36517209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Biginelli-based scaffolds as A
    Prieto-Díaz R; Fojo-Carballo H; Majellaro M; Tandarić T; Azuaje J; Brea J; Loza MI; Barbazán J; Salort G; Chotalia M; Rodríguez-Pampín I; Mallo-Abreu A; Rita Paleo M; García-Mera X; Ciruela F; Gutiérrez-de-Terán H; Sotelo E
    Biomed Pharmacother; 2024 Apr; 173():116345. PubMed ID: 38442670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Dihydropyrimidin-2(1
    Majellaro M; Jespers W; Crespo A; Núñez MJ; Novio S; Azuaje J; Prieto-Díaz R; Gioé C; Alispahic B; Brea J; Loza MI; Freire-Garabal M; Garcia-Santiago C; Rodríguez-García C; García-Mera X; Caamaño O; Fernandez-Masaguer C; Sardina JF; Stefanachi A; El Maatougui A; Mallo-Abreu A; Åqvist J; Gutiérrez-de-Terán H; Sotelo E
    J Med Chem; 2021 Jan; 64(1):458-480. PubMed ID: 33372800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Jiang J; Seel CJ; Temirak A; Namasivayam V; Arridu A; Schabikowski J; Baqi Y; Hinz S; Hockemeyer J; Müller CE
    J Med Chem; 2019 Apr; 62(8):4032-4055. PubMed ID: 30835463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
    Mallo-Abreu A; Prieto-Díaz R; Jespers W; Azuaje J; Majellaro M; Velando C; García-Mera X; Caamaño O; Brea J; Loza MI; Gutiérrez-de-Terán H; Sotelo E
    J Med Chem; 2020 Jul; 63(14):7721-7739. PubMed ID: 32573250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A
    Vlachodimou A; de Vries H; Pasoli M; Goudswaard M; Kim SA; Kim YC; Scortichini M; Marshall M; Linden J; Heitman LH; Jacobson KA; IJzerman AP
    Biochem Pharmacol; 2022 Jun; 200():115027. PubMed ID: 35395239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A
    Tay AHM; Prieto-Díaz R; Neo S; Tong L; Chen X; Carannante V; Önfelt B; Hartman J; Haglund F; Majellaro M; Azuaje J; Garcia-Mera X; Brea JM; Loza MI; Jespers W; Gutierrez-de-Teran H; Sotelo E; Lundqvist A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible Antagonists for the Adenosine A
    Temirak A; Schlegel JG; Voss JH; Vaaßen VJ; Vielmuth C; Claff T; Müller CE
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent-Labeled Selective Adenosine A
    Köse M; Gollos S; Karcz T; Fiene A; Heisig F; Behrenswerth A; Kieć-Kononowicz K; Namasivayam V; Müller CE
    J Med Chem; 2018 May; 61(10):4301-4316. PubMed ID: 29681156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of V6.51L as a selectivity hotspot in stereoselective A
    Wang X; Jespers W; Prieto-Díaz R; Majellaro M; IJzerman AP; van Westen GJP; Sotelo E; Heitman LH; Gutiérrez-de-Terán H
    Sci Rep; 2021 Jul; 11(1):14171. PubMed ID: 34238993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation.
    Vecchio EA; Tan CY; Gregory KJ; Christopoulos A; White PJ; May LT
    J Pharmacol Exp Ther; 2016 Apr; 357(1):36-44. PubMed ID: 26791603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
    Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
    J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.
    Eisenstein A; Patterson S; Ravid K
    J Cell Physiol; 2015 Dec; 230(12):2891-7. PubMed ID: 25975415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patent review of adenosine A
    Francucci B; Dal Ben D; Lambertucci C; Spinaci A; Volpini R; Marucci G; Buccioni M
    Expert Opin Ther Pat; 2022 Jun; 32(6):689-712. PubMed ID: 35387537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel xanthine derivatives as potent and selective A
    Basu S; Barawkar DA; Ramdas V; Patel M; Waman Y; Panmand A; Kumar S; Thorat S; Naykodi M; Goswami A; Reddy BS; Prasad V; Chaturvedi S; Quraishi A; Menon S; Paliwal S; Kulkarni A; Karande V; Ghosh I; Mustafa S; De S; Jain V; Banerjee ER; Rouduri SR; Palle VP; Chugh A; Mookhtiar KA
    Eur J Med Chem; 2017 Jul; 134():218-229. PubMed ID: 28415011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype.
    Merighi S; Borea PA; Gessi S
    Pharmacol Res; 2015 Sep; 99():229-36. PubMed ID: 26142494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.
    Vecchio EA; Chuo CH; Baltos JA; Ford L; Scammells PJ; Wang BH; Christopoulos A; White PJ; May LT
    Biochem Pharmacol; 2016 Oct; 117():46-56. PubMed ID: 27520486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
    Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
    J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New substituted 9-alkylpurines as adenosine receptor ligands.
    Camaioni E; Costanzi S; Vittori S; Volpini R; Klotz KN; Cristalli G
    Bioorg Med Chem; 1998 May; 6(5):523-33. PubMed ID: 9629466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists.
    Vazquez-Rodriguez S; Matos MJ; Santana L; Uriarte E; Borges F; Kachler S; Klotz KN
    J Pharm Pharmacol; 2013 May; 65(5):697-703. PubMed ID: 23600387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.